All In Biotech

BLA 125427 · Genentech

Kadcyla

Ado-Trastuzumab Emtansine · Single-Use

NovelBreakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Mar 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Feb 22, 2013

Approved uses

3

Original approval plus efficacy supplements

Registered trials

142

35 Phase 3, 21 recruiting

FAERS reports

8,459

6,979 serious, 1,171 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-FETAL TOXICITY Hepatotoxicity: Serious hepatotoxicity has been reported, including liver failure and death in patients treated with KADCYLA. Monitor serum transaminases and bilirubin prior to initiation of KADCYLA treatment and prior to each KADCYLA dose. Reduce dose or discontinue KADCYLA as appropriate in cases of increased serum transaminases or total bilirubin. ( 2.3 , 5.1 ) Cardiac Toxicity: KADCYLA administration may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate left ventricular function in all patients prior to and during treatment with KADCYLA. Withhold treatment for clinically significant decrease in left ventricular function. ( 2.3 , 5.2 ) Embryo-Fetal Toxicity: Exposure to KADCYLA during pregnancy can result in embryo-fetal harm. Advise patients of these risks and the need for effective...

What it is approved for

From the label in effect Apr 1, 2026.

KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. ( 1.1 ) the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. ( 1.2 ) Select patients for therapy based on an FDA-authorized test for KADCYLA [see Dosage and Administration (2.1) ] 1.1 Metastatic Breast Cancer (MBC) KADCYLA ® , as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: Received prior therapy for metastatic disease, or Developed disease recurrence during or within six months of completing adjuvant therapy. Select patients for therapy based on an FDA-authorized test for KADCYLA [ see Dosage and Administration (2.1) ]. 1.2 Early Breast Cancer (EBC) KADCYLA, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab -based treatment. Select patients for therapy based on an FDA-authorized test for KADCYLA [ see Dosage and Administration (2.1) ].

Mechanism: Ado-trastuzumab emtansine is a HER2-targeted antibody-drug conjugate. The antibody is the humanized anti-HER2 IgG1, trastuzumab. The small molecule cytotoxin, DM1, is a microtubule inhibitor. Upon binding to sub-domain IV of the HER2 receptor, ado-trastuzumab emtansine undergoes receptor-mediated internalization and subsequent lysosomal degradation, resulting in intracellular release of DM1-containing cytotoxic catabolites. Binding of DM1 to tubulin disrupts microtubule networks in the cell, which results in cell cycle arrest and apoptotic cell death. In addition, in vitro studies have shown...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • KADCYLA · ADO-TRASTUZUMAB EMTANSINE 100MG · VIAL, SINGLE-USE · Prescription
  • KADCYLA · ADO-TRASTUZUMAB EMTANSINE 160MG · VIAL, SINGLE-USE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ado-Trastuzumab Emtansine" as an intervention, any sponsor and status, largest first.

All 142 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • disease progression807
  • fatigue759
  • nausea741
  • off label use647
  • diarrhoea605
  • death565
  • thrombocytopenia485
  • neuropathy peripheral457
  • platelet count decreased438
  • headache436
  • metastases to central nervous system409
  • drug ineffective406

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201211
2013157
2014296
2015671
2016371
2017377
2018456
2019455
2020619
2021889
20221,039
20231,091
20241,085
2025635
2026307

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kadcyla (Ado-Trastuzumab Emtansine)

2024 spending

$4.1M

Beneficiaries

52

391 claims

Per beneficiary

$77,946

$4,332.58 per unit

View as table
YearSpending
2020$3,431,210
2021$4,777,613
2022$4,663,633
2023$3,847,823
2024$4,053,198

Part B: Kadcyla (Ado-Trastuzumab Emtansine) · HCPCS J9354

2024 spending

$142M

Beneficiaries

2,206

13,973 claims

Per beneficiary

$64,448

2024 ASP limit $39.32 per unit

View as table
YearSpending
2020$175,822,576
2021$182,463,589
2022$170,555,487
2023$144,605,154
2024$142,171,218

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 36 on PubMed
PubMed could not be reached. The numbers below may be missing or incomplete.

No PubMed clinical studies matched.

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.